Menu Search
Equities

Charles River Laboratories International Inc

CRL:NYQ

Charles River Laboratories International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)194.19
  • Today's Change6.29 / 3.35%
  • Shares traded2.46k
  • 1 Year change-0.39%
  • Beta1.3720
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Charles River Laboratories International Inc had little change in net income (from 486.23m to 474.62m) despite revenues that grew 3.86% from 3.98bn to 4.13bn.
Gross margin35.93%
Net profit margin10.54%
Operating margin13.00%
Return on assets5.48%
Return on equity11.66%
Return on investment6.33%
More ▼

Cash flow in USDView more

In 2023, Charles River Laboratories International Inc increased its cash reserves by 17.94%, or 43.27m. The company earned 683.90m from its operations for a Cash Flow Margin of 16.56%. In addition the company used 563.16m on investing activities and also paid 85.52m in financing cash flows.
Cash flow per share14.87
Price/Cash flow per share12.93
Book value per share73.97
Tangible book value per share-2.36
More ▼

Balance sheet in USDView more

Charles River Laboratories International Inc has a Debt to Total Capital ratio of 37.84%, a lower figure than the previous year's 76.05%.
Current ratio1.48
Quick ratio1.14
Total debt/total equity0.616
Total debt/total capital0.3784
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -2.67%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)15.57
EPS (TTM) vs
TTM 1 year ago		-13.24
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.